A Study of Motexafin Gadolinium for the Treatment of Relapsed or Refractory Multiple Myeloma

Completed · Phase 2

Conditions studied: Multiple Myeloma

In brief

The purpose of the study is to determine if the drug motexafin gadolinium will be an effective treatment for patients who have relapsed or refractory multiple myeloma.

Key facts

Study ID

NCT00096837

Run by

Pharmacyclics LLC.

People needed

25

Last updated by the study team

2006-06-08

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Relapsed or Refractory Multiple Myeloma
• ≥ 18 years old
• Able to provide consent for participation
• ECOG status 0-2
• Lab values:
• ANC ≥ 1,000/µL
• WBC count ≥ 2.0/µL
• Hemoglobin ≥ 8.0 g/dL
• Platelet count ≥ 50,000/µL
• AST and ALT ≤ 2 x ULN
• Total Bilirubin ≤ 2 x ULN
• Creatinine ≤ 2.0 mg/dL
• and
• Not pregnant or lactating

Where it is running

• Robert H. Lurie Comprehensive Cancer Center — Chicago, Illinois, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.